Introduction: Metastatic spread in invasive lobular carcinoma (ILC) of breast mainly occurs in bones, gynecological organs, peritoneum, retroperitoneum, and gastrointestinal (GI) tract. Metastases to the GI tract may arise many years after initial diagnosis and can affect the tract from the tongue to the anus, stomach being the most commonly involved site. Clinical presentations are predominantly nonspecific, and rarely asymptomatic. CEA, CA 15-3, and CA 19-9 may be informative for symptomatic patients who have had a previous history of breast cancer.
Introduction
Breast cancer represents the most common female malignancy. Although survival rates have been improving in the last few years, about 30% women will end up by developing a metastatic disease, irrespective of its treatment. [1, 2] Bones, lungs, pleura, liver, and brain are the main areas of metastasis from breast carcinoma. A considerable difference in metastatic patterns must be underlined when comparing invasive ductal carcinoma (IDC), which commonly involves lungs, pleura, and bones, with invasive lobular carcinoma (ILC) that frequently affects bones, gynecological organs, peritoneum, retroperitoneum, and gastrointestinal (GI) tract. [3, 4] Stomach and small intestine are the most frequent sites of GI tract, colonic and rectal metastases being very rare. [5, 6] Detection of GI metastasis originating from breast cancer often turns out difficult, above all in asymptomatic patients.
We introduce the case report of a silent isolated colonic metastasis that originated from ILC, 12 years from the primary tumor detection, whose diagnosis followed abdomen 18 Ffluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) and breast contrast-enhanced spectral mammography (CESM).
Case presentation
A 67-year-old woman followed up for Luminal A ILC at our Hospital showed an increased CEA and CA 15-3. In 2004, when 53 years old, she underwent a left radical mastectomy for an ILC [pT2N3(6/13), ER: 70%, PgR: 40%, KI67: 2%, HER2: negative]. After surgery, we administered 4 cycles of adjuvant chemotherapy based on epirubicin and cyclophosphamide and 4 cycles of taxotere, followed by a 2-year cycle of tamoxifene, then shifting to letrozole, for a global 5-year treatment.
She underwent annual Rx mammography, ultrasound (US) examination, and CEA and CA 15-3 markers screenings. The tests were negative until October 2016, when just a CEA and CA 15.3 increase was recorded (14.4 and 57 U/mL, with reference range 0.5-5.0 U/mL and 1-30 U/mL, respectively). No other symptoms or signs were reported by the patient. Due to negative traditional breast imaging, patient underwent total body CT scan followed by a colonoscopy, which were both negative. After a 3-month follow-up, CEA and CA 15-3 levels kept high. Therefore, the patient underwent a total body PET/CT scan, showing a FDG uptake of 4.7 and 1.9 Standardized Uptake Value (SUV), the former being suspicious for neoplastic lesion at level of ileocecal valve (Fig. 1A) , the latter being nonspecific at the level of right breast axillary tail (Fig. 1B) . A second colonoscopy showed a nonspecific, protruding, hyperemic, nonulcerated colonic wall area, easy to be missed by unguided colonoscopy, in proximity of (Fig. 2) . It showed a mild chronic inflammation of intestinal lamina propria, where epithelial cells marked by eccentric nucleus and broad vacuolated cytoplasm were detected, being consistent with localization of ILC of the breast. At immunohistochemistry, results were as follows: ER: 98% PgR: 95%, Ki67: 18%, HER2: negative. Multidisciplinary Group for Breast Cancer suggested contrastenhancement spectral mammography (CESM) in order to exclude ILC multifocality and/or multicentricity. It showed a contrast enhancement just at level of FDG uptake (Fig. 3) . At US second look of right breast, a 4-mm small ipoechoic area was detected. Biopsy result showed ILC (Fig. 4) . The patient was first referred to Surgical Oncology Unit, where right hemicolectomy was performed. Later, she was referred to Breast Unit for right breast quadrantectomy and lymph-node biopsy (negative result). After 7-month follow-up, no recurrence appeared.
Discussion
ILC of the breast accounts for 6% to 10% of all breast cancers. It has a different metastatic pattern if compared with IDCs, probably due to the loss of E-cadherin expression on tumor cell membrane that promotes tumor cell migration, preventing a cellto-cell adhesion. [7] From the radiology point of view, the loss of E-cadherin in ILC is also responsible for a difficult tumor detection, particularly in mammography, due to the absence of breast mass growth. [8] GI tract represents a rare site for metastatic breast disease, marked by lobular histology in most cases. Any GI tract can be involved, from the tongue to the anus. [9, 10] Clinical presentations are predominantly nonspecific (abdominal pain, diarrhea, inappetence, and nausea), peculiar (bleeding, vomiting) just in advanced cases, and rarely they are asymptomatic. [11] After a review of the literature up to 2017, stomach turned out as the most commonly affected site (65%) while only 14.9% metastases involved colon (32 in 214 reported cases). Only our case and case reported by Uskent et al [12] were found to be clinically symptomless (6.2%). In both cases, however, an increase of the screening markers was recorded (CEA and CA-15-3 in our case; just CA19-9 in Uskent et al).
Asymptomatic cases, where not only traditional imaging but also second-level techniques give negative results (such as CT and colonoscopy, as in our case), might lead to an underrating of clinical situation, missing the presence of a local or distant recurrence. To avoid this situation, we suggest to always perform www.md-journal.com 18 F-FDG PET/CT scan. In our case, 18 F-FDG PET/CT allowed to steer endoscopist to detect GI localization of the previously unnoted tumor, thus ruling out further dissemination in the remaining GI tract. CESM advantages over breast MRI are shorter examination times and lower costs. [13] Furthermore, CESM might be effective, when MRI is not available or in patients with contraindications (eg pacemakers or claustrophobia). Moreover, it represents a valuable tool for patients bearing the heavy psychological burden of examination for local or distant recurrence, after a first diagnosis and tumor treatment. CESM is more acceptable and feasible than MRI, as it reduces patient's stress. [14] In our case, CESM allowed a more accurate US second look of the breast, thus ruling out multicentricity and multifocality of breast localization, which are typical ILC features.
